MHRA
- Status: likely_approved
🇬🇧 Humira in United Kingdom
NICE has issued 11 UK HTA decisions
Marketing authorisations
MHRA
- Status: likely_approved
MHRA
- Status: likely_approved
MHRA
- Status: likely_approved
MHRA
- Status: likely_approved
Health technology assessment
11 decisions from NICE for Humira in United Kingdom.
NICE TA392 — ✓ Recommended
- Indication assessed: treating moderate to severe hidradenitis suppurativa
NICE recommended Humira for treating moderate to severe hidradenitis suppurativa. This decision was made based on the drug's clinical effectiveness and a patient access scheme was agreed upon. No commercial arrangement was involved and no restrictions were placed on the use of Humira for this indication.
NICE TA373 — ✓ Recommended
- Indication assessed: treating juvenile idiopathic arthritis
NICE recommended Humira for treating juvenile idiopathic arthritis. This decision was made based on a commercial arrangement and a patient access scheme. No restrictions were placed on the use of Humira for this indication.
NICE TA329 — ✓ Recommended
- Indication assessed: treating moderately to severely active ulcerative colitis after the failure of conventional therapy
NICE recommended Humira for treating moderately to severely active ulcerative colitis after conventional therapy failure. This decision was made based on a Patient Access Scheme and a commercial arrangement. No restrictions were placed on the use of Humira for this indication.
NICE TA715 — ✗ Not recommended
- Indication assessed: treating moderate rheumatoid arthritis after conventional DMARDs have failed
NICE made a decision not to recommend Humira for treating moderate rheumatoid arthritis after conventional DMARDs have failed. This decision was made for the United Kingdom. The cost basis of the decision is not reported. There are no restrictions or conditions associated with this decision.
NICE TA460 — ✓ Recommended
- Indication assessed: treating non-infectious uveitis
NICE recommended Humira for treating non-infectious uveitis. This decision was made without a Patient Access Scheme or commercial arrangement. No restrictions were placed on the use of Humira for this indication.
NICE TA455 — ✓ Recommended
- Indication assessed: treating plaque psoriasis in children and young people
NICE recommended Humira for treating plaque psoriasis in children and young people. This decision was made without a Patient Access Scheme or commercial arrangement. The restriction text was not specified.
NICE TA375 — ✗ Not recommended
- Indication assessed: rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
NICE made a decision not to recommend Humira for treating rheumatoid arthritis in patients who have not previously tried DMARDs or whose treatment with conventional DMARDs has failed. This decision was made without a reported ICER. A Patient Access Scheme and commercial arrangement were in place. There were no restrictions on the use of Humira.
NICE TA195 — ✓ Recommended
- Indication assessed: the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
NICE recommended Humira for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. This decision was made without a Patient Access Scheme. A commercial arrangement was in place. No restrictions were applied to the use of Humira for this indication.
NICE TA199 — — Decision pending classification
- Indication assessed: the treatment of psoriatic arthritis
NICE has made a decision regarding the use of Humira for the treatment of psoriatic arthritis. However, the details of the decision, including the cost basis and any restrictions, are not provided. The decision date is also not reported.
NICE TA187 — ✓ Recommended
- Indication assessed: the treatment of Crohn's disease
NICE recommended Humira for the treatment of Crohn's disease. This decision was made without a Patient Access Scheme or commercial arrangement. No restrictions were placed on the use of Humira for this indication.
NICE TA146 — ✓ Recommended
- Indication assessed: treating moderate to severe plaque psoriasis
NICE recommended Humira for treating moderate to severe plaque psoriasis. This decision was made without a Patient Access Scheme or commercial arrangement. No restrictions were placed on the use of Humira for this indication.
Humira in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Humira approved in United Kingdom?
Yes. MHRA has authorised it; MHRA has authorised it; MHRA has authorised it.
Who is the marketing authorisation holder for Humira in United Kingdom?
AbbVie is the originator. The local marketing authorisation holder may differ — check the official source linked above.
Has Humira been assessed by UK health technology agencies?
Yes — 11 UK HTA decisions on record from NICE.